We and others have shown the relevance of the expression of the Interleukin-2-Receptor α subunit (IL2RA/CD25) as a biomarker of CML progression, suggesting its potential use as a therapeutic target for CAR-based therapies. Here, IL2RA is linked to chronic myelogenous leukemia, BCR-ABL1 positive.